CYP2C8/9/18/19 Polyklonaler Antikörper
CYP2C8/9/18/19 Polyklonal Antikörper für WB, IHC, ELISA
Wirt / Isotyp
Kaninchen / IgG
Getestete Reaktivität
human, Maus, Ratte
Anwendung
WB, IHC, ELISA
Konjugation
Unkonjugiert
Kat-Nr. : 16546-1-AP
Synonyme
Geprüfte Anwendungen
| Erfolgreiche Detektion in WB | Mauslebergewebe, Rattenlebergewebe |
| Erfolgreiche Detektion in IHC | humanes Leberkarzinomgewebe Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen. |
Empfohlene Verdünnung
| Anwendung | Verdünnung |
|---|---|
| Western Blot (WB) | WB : 1:2000-1:10000 |
| Immunhistochemie (IHC) | IHC : 1:300-1:1200 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, check data in validation data gallery | |
Veröffentlichte Anwendungen
| WB | See 15 publications below |
| IHC | See 8 publications below |
Produktinformation
16546-1-AP bindet in WB, IHC, ELISA CYP2C8/9/18/19 und zeigt Reaktivität mit human, Maus, Ratten
| Getestete Reaktivität | human, Maus, Ratte |
| In Publikationen genannte Reaktivität | human, Maus, Ratte |
| Wirt / Isotyp | Kaninchen / IgG |
| Klonalität | Polyklonal |
| Typ | Antikörper |
| Immunogen | CYP2C8/9/18/19 fusion protein Ag9898 |
| Vollständiger Name | cytochrome P450, family 2, subfamily C, polypeptide 8 |
| Berechnetes Molekulargewicht | 490 aa, 56 kDa |
| Beobachtetes Molekulargewicht | 50 kDa |
| GenBank-Zugangsnummer | BC020596 |
| Gene symbol | CYP2C8 |
| Gene ID (NCBI) | 1558 |
| Konjugation | Unkonjugiert |
| Form | Liquid |
| Reinigungsmethode | Antigen-Affinitätsreinigung |
| Lagerungspuffer | PBS with 0.02% sodium azide and 50% glycerol |
| Lagerungsbedingungen | Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA. |
Hintergrundinformationen
CYP2C8(Cytochrome P450 2C8) is also named as CYPIIC8, cytochrome P450 IIC2, cytochrome P450 MP-12, cytochrome P450 MP-20, cytochrome P450 form 1 and S-mephenytoin 4-hydroxylase. It belongs to the cytochrome P450 family. It is a monooxygenase involved in an NADPH-dependent electron transport pathway and a hepatic drug-metabolizing enzymes that oxidizes therapeutic drugs such as cerivastatin and endobiotics such as retinoic acid and arachidonic acid. It has 2 isoforms produced by alternative splicing. This antibody can recognize human CYP2C 8/9/18/19, mouse CYP2C 29/37/38/39/55/65/, rat CYP2C6/7/11/12/13/23 due to the high homology.
Protokolle
| PRODUKTSPEZIFISCHE PROTOKOLLE | |
|---|---|
| WB protocol for CYP2C8/9/18/19 antibody 16546-1-AP | Protokoll herunterladen |
| IHC protocol for CYP2C8/9/18/19 antibody 16546-1-AP | Protokoll herunterladenl |
| STANDARD-PROTOKOLLE | |
|---|---|
| Klicken Sie hier, um unsere Standardprotokolle anzuzeigen |
Publikationen
| Species | Application | Title |
|---|---|---|
Cell Chem Biol 3D two-photon brain imaging reveals dihydroartemisinin exerts antiepileptic effects by modulating iron homeostasis. | ||
Front Oncol Prognostic Value and Correlation With Tumor Immune Infiltration of a Novel Metabolism-Related Gene Signature in Pancreatic Cancer. | ||
Front Oncol Novel Prognostic Signatures of Hepatocellular Carcinoma Based on Metabolic Pathway Phenotypes. | ||
Pharmaceutics Assessing CYP2C8-Mediated Pharmaceutical Excipient-Drug Interaction Potential: A Case Study of Tween 80 and Cremophor EL-35. | ||
Front Pharmacol Mechanism of Paeoniflorin on ANIT-Induced Cholestatic Liver Injury Using Integrated Metabolomics and Network Pharmacology. | ||
BMC Cancer Elevated 14,15- epoxyeicosatrienoic acid by increasing of cytochrome P450 2C8, 2C9 and 2J2 and decreasing of soluble epoxide hydrolase associated with aggressiveness of human breast cancer. |


